A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies
Running, not enrolling · Phase 1/Phase 2
Conditions studied: Solid Tumor, Clear Cell Renal Cell Carcinoma, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Neuroendocrine Tumors, MSI-H Cancer, Cancer With A High Tumor Mutational Burden, Extensive-stage Small-cell Lung Cancer
In brief
This is a first-in-human open-label Phase 1/2a study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of 23ME-00610 given by intravenous infusion in patients with advanced solid malignancies who have progressed on all available standard therapies
Key facts
- Study ID
- NCT05199272
- Run by
- 23andMe, Inc.
- People needed
- 141
- Starts
- 2021-12-29
- Expected to finish
- 2025-03-01
- Last updated by the study team
- 2024-11-15
Who can join
Age: 12 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Stanford Cancer Institute — Palo Alto, California, United States
- Emory University — Atlanta, Georgia, United States
- Karmanos Cancer Institute — Detroit, Michigan, United States
- R.J.Zuckerberg Cancer Center — Lake Success, New York, United States
- Cohen Children's Medical Center — New Hyde Park, New York, United States
- Oregon Health & Science University — Portland, Oregon, United States
- Vanderbilt University — Nashville, Tennessee, United States
- MD Anderson Cancer Center — Houston, Texas, United States
- START Center for Cancer Care — San Antonio, Texas, United States
- Virginia Cancer Specialists — Fairfax, Virginia, United States
- Ottawa Hospital Cancer Centre — Ottawa, Ontario, Canada
- Princess Margaret Cancer Centre — Toronto, Ontario, Canada
- The Hospital for Sick Children — Toronto, Ontario, Canada
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.